



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
JOCKERS et al.

Examiner: **Wollenberger, Louis**

Art Unit: **1635**

Application No.: **10/774,721**

Filed: **February 9, 2004**

**Title: OLIGONUCLEOTIDES WHICH INHIBIT
EXPRESSION OF THE OB-RGRP PROTEIN AND
METHOD FOR DETECTING COMPOUNDS
WHICH MODIFY THE INTERACTION
BETWEEN PROTEINS OF THE OB-RGRP
FAMILY AND THE LEPTIN RECEPTOR**

I hereby certify that this correspondence is being deposited with
the United States Postal Service as First Class Mail in an envelope
addressed to Mail Stop Sequence, Commissioner for Patents, P.O.
Box 1450, Alexandria, VA 22313-1450, on

May 19, 2006
Date of Deposit
Debra Coughlin
Signature

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop Sequence
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed substitute pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the substitute copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

George S. Jones, Reg. No. 38,508
Attorney/Agent for Applicant

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3776
Telefax (908) 231-2626

sanofi-aventis Docket No. FRAV2003/0005 US NP



Notice to Comply	Application No. 10/774721	Applicant(s) Jockers et al.	
	Examiner Louis V. Wollenberger	Art Unit 1635	
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES			
Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).			
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):			
<input type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).			
<input type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).			
<input type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).			
<input checked="" type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."			
<input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).			
<input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).			
<input type="checkbox"/> 7. Other:			
Applicant Must Provide:			
<input checked="" type="checkbox"/> An initial <u>or</u> substitute computer readable form (CRF) copy of the "Sequence Listing".			
<input checked="" type="checkbox"/> An initial <u>or</u> substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.			
<input checked="" type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).			
For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (571) 272-2510 For CRF Submission Help, call (571) 272-2501/2583. PatentIn Software Program Support Technical Assistance.....703-287-0200 To Purchase PatentIn Software.....703-306-2600			
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY			